FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:375 August 1, 2002 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

By John D. Lantos. 183 pp. Baltimore, Johns Hopkins University Press, 2001. $22.50. ISBN 0-8018-6762-2.

Neonatal intensive care is one of the most dramatic recent advances in medicine. Every year, 53,000 babies are born prematurely in the United States. The newborn intensive care unit, with its sophisticated technology, has become the artificial womb for these infants, and although most infants treated in this unit go on to lead full and productive lives, others are left with multiple problems, such as blindness, seizures, chronic lung disease, and neurologic damage. This is one reason the health care system in the United States is sometimes seen as mindlessly driven by a technological imperative.

In The Lazarus Case, John . . . [Full Text of this Article]

This article has been cited by other articles:

• Kassahun, K., McIntosh, I., Cui, D., Hreniuk, D., Merschman, S., Lasseter, K., Azrolan, N., Iwamoto, M., Wagner, J. A., Wenning, L. A. (2007). Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme. Drug Metab. Dispos. 35: 1657-1663 [Abstract] [Full Text]